Company Profile

Astex Therapeutics Limited (AKA: SuperGen Inc)
Profile last edited on: 12/3/2023      CAGE: 3R9X1      UEI: ZRGCA6NF7VT3

Business Identifier: In-licenser and developer of drug candidates for cancer or immune conditions
Year Founded
First Award
Latest Award
Program Status
Inactive (Acquired)
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

4140 Dublin Boulevard Suite 200
Dublin, CA 94568
   (925) 560-0100
Location: Single
Congr. District: 10
County: Alameda

Public Profile

SuperGen, Inc. had been a pharmaceutical company organized around oncology therapies for solid tumors, hematological malignancies and blood disorders - ahving three key compounds: Nipent, Orathecin and Decitabine - Nipent having been approved by the United States Food and Drug Administration (FDA) and marketed by the Company for the treatment of hairy cell leukemia. As of April 2007, Mitomycin and Paclitaxel rights of SuperGen, Inc., were acquired by Intas Pharmaceuticals Ltd. In 2011, Astex Therapeutics Limited (“Astex”), a privately held, UK-based biotechnology company developing targeted therapies. became a wholly owned subsidiay of SuperGen, Inc. Later that year, SuperGen changed its own Corporate Mame to Astex Pharmaceuticals, Inc., and from that point, was listed on NASDAQ under the symbol ASTX. In Fall 2013, Japanese drug and nutraceuticals firm Otsuka Pharmaceutical Co. Ltd. acquire Astex Pharmaceuticals Inc. for a reported $886mm. Shortly therafter Astex Pharmaceuticals Inc. and Genentech Inc. entered into a trial collaboration agreement to investigate the combination of Astex' guadecitabine with Genentech's atezolizumab for acute myeloid leukemia.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
VC funded?
Publicly Traded
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2002 1 NIH $141,389
Project Title: Therapeutic management of SIRS with pentostatin
2000 1 NIH $107,311
Project Title: Chymase Inhibitors--Treatment of Cardiovascular Disease

Key People / Management

  James Manuso -- CEO

  William R Law